Bio-Rad Laboratories, Inc. $BIO Stake Boosted by Natixis Advisors LLC

Natixis Advisors LLC grew its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 70,916 shares of the medical research company’s stock after purchasing an additional 5,847 shares during the quarter. Natixis Advisors LLC owned approximately 0.26% of Bio-Rad Laboratories worth $21,487,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in BIO. First Eagle Investment Management LLC boosted its position in shares of Bio-Rad Laboratories by 2.0% during the fourth quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock worth $778,828,000 after buying an additional 50,154 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Bio-Rad Laboratories by 6.3% during the third quarter. Dimensional Fund Advisors LP now owns 1,062,938 shares of the medical research company’s stock worth $298,019,000 after buying an additional 63,370 shares during the period. Earnest Partners LLC boosted its position in shares of Bio-Rad Laboratories by 0.6% during the third quarter. Earnest Partners LLC now owns 609,284 shares of the medical research company’s stock worth $170,837,000 after buying an additional 3,398 shares during the period. Bank of America Corp DE boosted its position in shares of Bio-Rad Laboratories by 1.7% during the third quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after buying an additional 7,754 shares during the period. Finally, Capital Research Global Investors acquired a new position in shares of Bio-Rad Laboratories during the third quarter worth approximately $117,303,000. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $294.01 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $219.42 and a 1-year high of $343.12. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $7.87 billion, a price-to-earnings ratio of 48.44 and a beta of 1.08. The stock’s fifty day simple moving average is $282.12 and its 200-day simple moving average is $291.70.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The business had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. During the same quarter in the prior year, the firm posted $2.54 EPS. The business’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BIO. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price objective for the company. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $303.33.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.